Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
AbstractAntibody–drug conjugates (ADCs), constructed with monoclonal antibodies (mAbs), linkers, and natural cytotoxins, are innovative drugs developed for oncotherapy. Owing to the distinctive advantages of both chemotherapy drugs and antibody drugs, ADCs have obtained enormous success during the past several years. The development of highly specific antibodies, novel marine toxins’ applications, and innovative linker technologies all accelerate the rapid R&D of ADCs. Meanwhile, some challenges remain to be solved for future ADCs. For instance, varieties of site-specific conjugation have been proposed for solving the inhomogeneity of DARs (Drug Antibody Ratios). In this review, the usages of various natural toxins, especially marine cytotoxins, and the development strategies for ADCs in the past decade are summarized. Representative ADCs with marine cytotoxins in the pipeline are introduced and characterized with their new features, while perspective comments for future ADCs are proposed. View Full-Text
Share & Cite This Article
Wang, Y.-J.; Li, Y.-Y.; Liu, X.-Y.; Lu, X.-L.; Cao, X.; Jiao, B.-H. Marine Antibody–Drug Conjugates: Design Strategies and Research Progress. Mar. Drugs 2017, 15, 18.
Wang Y-J, Li Y-Y, Liu X-Y, Lu X-L, Cao X, Jiao B-H. Marine Antibody–Drug Conjugates: Design Strategies and Research Progress. Marine Drugs. 2017; 15(1):18.Chicago/Turabian Style
Wang, Yu-Jie; Li, Yu-Yan; Liu, Xiao-Yu; Lu, Xiao-Ling; Cao, Xin; Jiao, Bing-Hua. 2017. "Marine Antibody–Drug Conjugates: Design Strategies and Research Progress." Mar. Drugs 15, no. 1: 18.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.